BIOMAT Database Logo BIOMAT Database Logo

The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. 1993

T D Egan, and H J Lemmens, and P Fiset, and D J Hermann, and K T Muir, and D R Stanski, and S L Shafer
Department of Anesthesiology, University of Utah School of Medicine, Salt Lake City 84132.

BACKGROUND Remifentanil (GI87084B) is a new short-acting opioid with a unique ester structure. Metabolism of remifentanil by ester hydrolysis results in very rapid elimination. The aim of this study was to characterize in detail the pharmacokinetic profile of remifentanil in healthy male volunteers. METHODS Ten healthy adult male volunteers received a zero-order infusion of remifentanil at doses ranging from 1 to 8 micrograms.kg-1.min-1 for 20 min. Frequent arterial blood samples were drawn and analyzed by gas chromatographic mass spectroscopy to determine the remifentanil blood concentrations. The raw pharmacokinetic data were analyzed using three different parametric compartmental modeling methods (traditional two-stage, naive pooled data, and NONMEM). The raw pharmacokinetic data also were analyzed using numeric deconvolution and a nonparametric moment technique. A computer simulation using hte pharmacokinetic parameters of the NONMEM compartmental model was performed to provide a more intuitively meaningful and clinically relevant description of the pharmacokinetics. The simulation estimated the time necessary to achieve a 50% decrease in remifentanil concentration after a variable-length infusion. RESULTS For each parametric method, a three-compartment mamillary model that accurately describes remifentanil's concentration decay curve was constructed. The NONMEM analysis population pharmacokinetic parameters included a central clearance of 2.8 l/min, a volume of distribution at steady state of 32.8 l, and a terminal half-life of 48 min. The mean results of the nonparametric moment analysis included a clearance of 2.9 l/min, a volume of distribution at steady state of 31.8 l, and a mean residence time of 10.9 min. The computer simulation revealed the strikingly unique pharmacokinetic profile of remifentanil compared to that of the currently available fentanyl family of opioids. CONCLUSIONS Remifentanil is a new, short-acting opioid with promising clinical potential in anesthesiology.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D010880 Piperidines A family of hexahydropyridines.
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D003198 Computer Simulation Computer-based representation of physical systems and phenomena such as chemical processes. Computational Modeling,Computational Modelling,Computer Models,In silico Modeling,In silico Models,In silico Simulation,Models, Computer,Computerized Models,Computer Model,Computer Simulations,Computerized Model,In silico Model,Model, Computer,Model, Computerized,Model, In silico,Modeling, Computational,Modeling, In silico,Modelling, Computational,Simulation, Computer,Simulation, In silico,Simulations, Computer
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077208 Remifentanil A piperidine-propionate derivative and opioid analgesic structurally related to FENTANYL. It functions as a short-acting MU OPIOID RECEPTOR agonist, and is used as an analgesic during induction or maintenance of general anesthesia, following surgery, during childbirth, and in mechanically ventilated patients under intensive care. 3-(4-Methoxycarbonyl-4-((1-oxopropyl)phenylamino)-1-piperidine)propanoic Acid Methyl Ester,GI 87084B,GI-87084B,GI87084B,Remifentanil Hydrochloride,Remifentanil Monohydrochloride,Ultiva
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000701 Analgesics, Opioid Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. Opioid,Opioid Analgesic,Opioid Analgesics,Opioids,Full Opioid Agonists,Opioid Full Agonists,Opioid Mixed Agonist-Antagonists,Opioid Partial Agonists,Partial Opioid Agonists,Agonist-Antagonists, Opioid Mixed,Agonists, Full Opioid,Agonists, Opioid Full,Agonists, Opioid Partial,Agonists, Partial Opioid,Analgesic, Opioid,Full Agonists, Opioid,Mixed Agonist-Antagonists, Opioid,Opioid Agonists, Full,Opioid Agonists, Partial,Opioid Mixed Agonist Antagonists,Partial Agonists, Opioid

Related Publications

T D Egan, and H J Lemmens, and P Fiset, and D J Hermann, and K T Muir, and D R Stanski, and S L Shafer
Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers.
April 1996, Anesthesiology,
T D Egan, and H J Lemmens, and P Fiset, and D J Hermann, and K T Muir, and D R Stanski, and S L Shafer
The pharmacokinetics of ofloxacin in healthy adult male volunteers.
January 1987, European journal of clinical pharmacology,
T D Egan, and H J Lemmens, and P Fiset, and D J Hermann, and K T Muir, and D R Stanski, and S L Shafer
Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B).
November 1993, Anesthesia and analgesia,
T D Egan, and H J Lemmens, and P Fiset, and D J Hermann, and K T Muir, and D R Stanski, and S L Shafer
Remifentanil: a novel, short-acting, mu-opioid.
September 1996, Anesthesia and analgesia,
T D Egan, and H J Lemmens, and P Fiset, and D J Hermann, and K T Muir, and D R Stanski, and S L Shafer
The pharmacokinetics and extra-hepatic clearance of remifentanil, a short acting opioid agonist, in male beagle dogs during constant rate infusions.
January 1996, Drug metabolism and disposition: the biological fate of chemicals,
T D Egan, and H J Lemmens, and P Fiset, and D J Hermann, and K T Muir, and D R Stanski, and S L Shafer
Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers.
November 2003, Clinical therapeutics,
T D Egan, and H J Lemmens, and P Fiset, and D J Hermann, and K T Muir, and D R Stanski, and S L Shafer
Effects of environmental enrichment on self-administration of the short-acting opioid remifentanil in male rats.
December 2017, Psychopharmacology,
T D Egan, and H J Lemmens, and P Fiset, and D J Hermann, and K T Muir, and D R Stanski, and S L Shafer
Effects of the opioid remifentanil on olfactory function in healthy volunteers.
September 2001, Life sciences,
T D Egan, and H J Lemmens, and P Fiset, and D J Hermann, and K T Muir, and D R Stanski, and S L Shafer
Pharmacokinetics of losigamone, a new antiepileptic drug, in healthy male volunteers.
January 1996, International journal of clinical pharmacology and therapeutics,
T D Egan, and H J Lemmens, and P Fiset, and D J Hermann, and K T Muir, and D R Stanski, and S L Shafer
The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers.
July 2002, Clinical therapeutics,
Copied contents to your clipboard!